Genetic analysis helps increase clinical benefits with PARP inhibitors in ovarian cancer and BRCA

The use of genetic testing to identify homologous recombination deficiency (HRD) and BRCA Mutations in ovarian cancer could better aid selection of frontline maintenance therapies and improve management of toxicities associated with PARP inhibitors, according to Sakth Guntopalli, MD. “We go in [a new] The age of the ovarian cancer molecule,” Guntupalli said following OncLive® … Read more